SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas

Archive ouverte

Idbaih, Ahmed | Ducray, François | Dehais, Caroline | Courdy, Célia | Carpentier, Catherine | de Bernard, Simon | Uro-Coste, Emmanuelle | Mokhtari, Karima | Jouvet, Anne | Honnorat, Jérôme | Chinot, Olivier | Ramirez, Carole | Beauchesne, Patrick | Benouaich-Amiel, Alexandra | Godard, Joël | Eimer, Sandrine | Parker, Fabrice | Lechapt-Zalcman, Emmanuelle | Colin, Philippe | Loussouarn, Delphine | Faillot, Thierry | Dam-Hieu, Phong | Elouadhani-Hamdi, Selma | Bauchet, Luc | Langlois, Olivier | Le Guerinel, Caroline | Fontaine, Denys | Vauleon, Elodie | Menei, Philippe | Fotso, Marie Janette Motsuo | Desenclos, Christine | Verrelle, Pierre | Ghiringhelli, François | Noel, Georges | Labrousse, François | Carpentier, Antoine | Dhermain, Frédéric | Delattre, Jean-Yves | Figarella-Branger, Dominique

Edité par CCSD ; Public Library of Science -

International audience. Anaplastic oligodendrogliomas (AOD) are rare glial tumors in adults with relative homogeneous clinical, radiological and histological features at the time of diagnosis but dramatically various clinical courses. Studies have identified several molecular abnormalities with clinical or biological relevance to AOD (e.g. t(1;19)(q10;p10), IDH1, IDH2, CIC and FUBP1 mutations).To better characterize the clinical and biological behavior of this tumor type, the creation of a national multicentric network, named "Prise en charge des OLigodendrogliomes Anaplasiques (POLA)," has been supported by the Institut National du Cancer (InCA). Newly diagnosed and centrally validated AOD patients and their related biological material (tumor and blood samples) were prospectively included in the POLA clinical database and tissue bank, respectively.At the molecular level, we have conducted a high-resolution single nucleotide polymorphism array analysis, which included 83 patients. Despite a careful central pathological review, AOD have been found to exhibit heterogeneous genomic features. A total of 82% of the tumors exhibited a 1p/19q-co-deletion, while 18% harbor a distinct chromosome pattern. Novel focal abnormalities, including homozygously deleted, amplified and disrupted regions, have been identified. Recurring copy neutral losses of heterozygosity (CNLOH) inducing the modulation of gene expression have also been discovered. CNLOH in the CDKN2A locus was associated with protein silencing in 1/3 of the cases. In addition, FUBP1 homozygous deletion was detected in one case suggesting a putative tumor suppressor role of FUBP1 in AOD.Our study showed that the genomic and pathological analyses of AOD are synergistic in detecting relevant clinical and biological subgroups of AOD.

Suggestions

Du même auteur

Survival outcomes associated with first-line procarbazine, CCNU, and Vincristine or Temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma

Archive ouverte | Kacimi, Salah Eddine O. | CCSD

International audience. Purpose: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3IDHmt/Codel) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemo...

Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas

Archive ouverte | Figarella-Branger, Dominique | CCSD

CERVOXY COLL. International audience

Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis

Archive ouverte | Figarella-Branger, Dominique | CCSD

CERVOXY COLL. International audience

Chargement des enrichissements...